Twice-yearly injection cuts HIV risk by 96%, but will cost cut access?
A groundbreaking trial has revealed that a twice-yearly injection of lenacapavir could significantly reduce the risk of HIV infection, offering hope for millions worldwide. Developed by Gilead Sciences, this new HIV prevention method shows an impressive 96% effectiveness, surpassing the daily oral pill, Truvada. However, concerns about cost and access have sparked debates among healthcare […]







